NCT Number: NCT01791725
A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
This is a prospective, randomized, double-blind, placebo-controlled, parallel-group, three-arm, multicenter study of the safety and PK of ELND005 administered orally for 4 weeks. This study will enroll Down Syndrome patients 18 to 45 years of age (inclusive) without dementia.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–45 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
University of California, San Diego, La Jolla, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- 18 - 45 years of age
- Has an IQ of > 40 (K-BIT)
- Able and willing to have a brain MRI
Exclusion criteria
- Symptoms of dementia or worsening cognition over the past year.
- Has a history of hepatitis B, hepatitis C, or HIV
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Incidence of Adverse Events (TEAEs)
Time frame: 4 weeks
For all AE summaries, if a patient had more than one AE within a preferred term, the patient was counted only once, at the maximum severity and with the closest relationship to study drug. If a patient had more than one AE within a SOC, the subject was similarly counted only once when reporting results for that SOC.
Other outcomes
-
Changes From Baseline in Abnormal Neurological Examination Results
Time frame: Baseline and 4 weeks
Subjects with Abnormal Neurological Examination Results
-
Pharmacokinetic Assessment
Time frame: Baseline and 4 Weeks
Mean Plasma ELND005 Concentrations- Cmax
-
Cognitive Outcome (RADD Total Score)
Time frame: Baseline and 4 Weeks
Rapid Assessment for Development Disabilities (RADD) The RADD test was developed from the low-difficulty items from published intelligence tests (Walsh et al 2007). It was specifically developed for evaluation of individuals with intellectual disabilities and developmental disabilities. It is a validated and reliable cognitive screening instrument that can be rapidly administered. The RADD is composed of 76 items. Each item is scored as 0 (incorrect) or 1 (correct).The test assesses a wide range of functional abilities including receptive and expressive language, orientation, registration, recall, attention, self identification, motor skills, imitation, abstract reasoning, number skills, comprehension and short-term memory to give a total score. Scores are from 0 to 76. A higher total score is correlated with a higher Cognitive Impairment level.
-
Improvement in NPI Total Scores in Subjects With NPI Score ≥1 at Baseline Baseline
Time frame: Baseline and 4 weeks
The Neuropsychiatric Inventory(NPI) (Cummings et al 1994) is a behavioral measure that assesses psychopathology in dementia patients. The NPI was administered at the Baseline Visit (Day 1) and at Day 28 (EOS) or ET. A decrease in score shows an improvement in symptoms.
Sponsors and collaborators
Lead sponsor
OPKO Health, Inc.
Industry
Collaborators
- Elan Pharmaceuticals
Registry information
Official study title
A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Acronym: DS201
Important dates
- Study start
- 2013
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Feb 15, 2013
- Registry last updated
- Nov 4, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
MOTOR PROFICIENCY AND HEALTH-RELATED FITNESS IN DOWN SYNDROME
NCT07702201
Abnormalities, Multiple, Chromosome Disorders
Giza, Eldoky, Egypt
View Trial DetailsTherapies for Down Syndrome Regression Disorder
NCT05662228
Abnormalities, Multiple, Autoimmune Diseases
Los Angeles, California, United States
View Trial DetailsThe (Cost)Effectiveness of a Social Robot for Persons With Problems in Daily Structure and Planning in Disability Care
NCT06592404
Abnormalities, Multiple, Autism Spectrum Disorder
Sittard, Limburg, Netherlands
View Trial DetailsLeucettinib-21 First-in-Human Phase 1 in Healthy Volunteers and Subjects With Down Syndrome and Alzheimer's Disease
NCT06206824
Abnormalities, Multiple, Alzheimer Disease
Gières, France
View Trial Details